Zacks: Analysts Expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to Post -$0.99 EPS

Brokerages expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to post earnings per share of ($0.99) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Five Prime Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.90) and the lowest estimate coming in at ($1.11). Five Prime Therapeutics reported earnings of ($1.37) per share during the same quarter last year, which suggests a positive year over year growth rate of 27.7%. The firm is expected to announce its next earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Five Prime Therapeutics will report full-year earnings of ($3.89) per share for the current year, with EPS estimates ranging from ($4.27) to ($3.34). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.75) per share, with EPS estimates ranging from ($3.95) to ($2.03). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.09). The company had revenue of $3.33 million during the quarter, compared to the consensus estimate of $5.53 million. Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 58.69%.



Several research firms have recently weighed in on FPRX. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 6th. ValuEngine upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Co lowered shares of Five Prime Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $35.00 to $10.00 in a research note on Monday, June 3rd. BidaskClub lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Finally, Roth Capital began coverage on shares of Five Prime Therapeutics in a research note on Wednesday, May 29th. They issued a “neutral” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Five Prime Therapeutics has an average rating of “Hold” and an average price target of $20.00.

Shares of NASDAQ:FPRX traded down $0.16 during mid-day trading on Wednesday, hitting $5.59. The company had a trading volume of 287,800 shares, compared to its average volume of 382,569. The company has a fifty day moving average of $5.60. The firm has a market capitalization of $199.77 million, a P/E ratio of -1.35 and a beta of 2.58. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.41 and a quick ratio of 10.41. Five Prime Therapeutics has a one year low of $4.89 and a one year high of $16.00.

A number of hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its holdings in shares of Five Prime Therapeutics by 1,691.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,374 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 5,074 shares in the last quarter. Alambic Investment Management L.P. acquired a new stake in Five Prime Therapeutics during the second quarter worth $69,000. Bailard Inc. increased its stake in Five Prime Therapeutics by 23.8% during the second quarter. Bailard Inc. now owns 13,000 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 2,500 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Five Prime Therapeutics by 1,929.9% during the first quarter. BNP Paribas Arbitrage SA now owns 7,328 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 6,967 shares during the last quarter. Finally, Athanor Capital LP acquired a new stake in Five Prime Therapeutics during the second quarter worth $104,000. Institutional investors and hedge funds own 86.09% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Read More: What does a hold rating mean?

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.